drugset / Trial / NCT04782804
Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence
Non-randomizedParallel-groupOpen-labelPrevention
Summary
The purpose of the study is to observe the effect of PD-1 Antibody（Tislelizumab） Combined With Capecitabine as Adjuvant Therapy to Prevent the Recurrence in High-risk Patients With Cholangiocarcinoma After Curative Resection.
Timeline
- Start
- 2021-01-01
- Primary completion
- 2023-12-30
- Completion
- 2024-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1250 mg/m2 | Oral |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |